$940.1M in CY2024 Part D spend379K claims · 55K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Dolutegravir used for?
TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
Is there a generic for Dolutegravir?
No. Dolutegravir is brand-only with no generic equivalents currently in market.
How much does my plan pay for Dolutegravir?
Across 329 Part D plans, Dolutegravir averages $77.66/unit (NADAC). Lowest available: $77.66/unit. Highest in distribution: $77.66/unit.
Is Dolutegravir on the FDA shortage list?
No. Dolutegravir is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.